Inhibition of K562 leukemia angiogenesis and growth by expression of antisense vascular endothelial growth factor (VEGF) sequence

• Published in: Cancer gene therapy Vol. 10; no. 12; pp. 879 - 886
• Main Authors: He, Rui, Liu, Bin, Yang, Chen, Yang, Ren Chi, Tobelem, Gerard, Han, Zhong Chao
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.12.2003
• Subjects: Angiogenesis; Apoptosis; Care and treatment; Cell Line, Tumor; Cell proliferation; Cell Survival; DNA, Antisense; Down-Regulation; Endothelial cells; Erythroleukemia; Genetic aspects; Genetic Therapy; Genetic Vectors; Health aspects; Humans; Leukemia; Leukemia, Erythroblastic, Acute - pathology; Neovascularization; Neovascularization, Pathologic; Physiological aspects; Solid tumors; Umbilical vein; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - biosynthesis; Vascular Endothelial Growth Factor A - genetics; Vascular Endothelial Growth Factor A - pharmacology; China
• ISSN: 0929-1903; 1476-5500
• DOI: 10.1038/sj.cgt.7700645

Vascular endothelial growth factor (VEGF), a major angiogenic factor, plays a key role in the growth of solid tumor. Recently, expression of VEGF and its receptors has been found on leukemic cells as well as on endothelial cells. VEGF may fulfill a fundamental role in promoting tumor angiogenesis and proliferation by stimulating both endothelial cells and leukemic cells. To investigate the role of VEGF in the angiogenesis and growth of leukemic cell, we used an antisense strategy to downregulate VEGF expression in K562 cells, a human erythroleukemia cell line. Expression of antisense-VEGF in K562 cells reduced the secretion of VEGF protein and inhibited cell survival. The proliferation and migration of human umbilical vein endothelial cells were decreased in response to the conditioned medium (CM) from K562 cells expressed antisense-VEGF, compared to CM from K562 cells transfected with vector control. Moreover, subcutaneous injection of nude mice with antisense-VEGF K562 cells inhibited tumor growth with a reduction of the density of microvessels and an increased apoptosis in those tumors, compared to vector control K562 cells. These results suggest that the efficient downregulation of the VEGF production in leukemic cells using antisense-VEGF may constitute a novel strategy of treatment in leukemia.